Literature DB >> 18507379

Total synthesis and molecular target of largazole, a histone deacetylase inhibitor.

Yongcheng Ying1, Kanchan Taori, Hyoungsu Kim, Jiyong Hong, Hendrik Luesch.   

Abstract

Full details of the concise and convergent synthesis (eight steps, 19% overall yield), its extension to the preparation of a series of key analogues, and the molecular target and pharmacophore of largazole are described. Central to the synthesis of largazole is a macrocyclization reaction for formation of the strained 16-membered depsipeptide core followed by an olefin cross-metathesis reaction for installation of the thioester. The biological evaluation of largazole and its key analogues, including an acetyl analogue, a thiol analogue, and a hydroxyl analogue, suggested that histone deacetylases (HDACs) are molecular targets of largazole and largazole is a class I HDAC inhibitor. In addition, structure-activity relationship (SAR) studies revealed that the thiol group is the pharmacophore of the natural product. Largazole's HDAC inhibitory activity correlates with its antiproliferative activity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18507379     DOI: 10.1021/ja8013727

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  69 in total

1.  Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents.

Authors:  Sajal K Ghosh; Susan P Perrine; Robert M Williams; Douglas V Faller
Journal:  Blood       Date:  2011-12-07       Impact factor: 22.113

Review 2.  Macrocyclic histone deacetylase inhibitors.

Authors:  Sandra C Mwakwari; Vishal Patil; William Guerrant; Adegboyega K Oyelere
Journal:  Curr Top Med Chem       Date:  2010       Impact factor: 3.295

3.  Largazole and analogues with modified metal-binding motifs targeting histone deacetylases: synthesis and biological evaluation.

Authors:  Pravin Bhansali; Christin L Hanigan; Robert A Casero; L M Viranga Tillekeratne
Journal:  J Med Chem       Date:  2011-10-10       Impact factor: 7.446

4.  Epigenetic changes induced by curcumin and other natural compounds.

Authors:  Simone Reuter; Subash C Gupta; Byoungduck Park; Ajay Goel; Bharat B Aggarwal
Journal:  Genes Nutr       Date:  2011-04-24       Impact factor: 5.523

5.  Largazole is a Brain-Penetrant Class I HDAC Inhibitor with Extended Applicability to Glioblastoma and CNS Diseases.

Authors:  Fatma H Al-Awadhi; Lilibeth A Salvador-Reyes; Lobna A Elsadek; Ranjala Ratnayake; Qi-Yin Chen; Hendrik Luesch
Journal:  ACS Chem Neurosci       Date:  2020-06-19       Impact factor: 4.418

Review 6.  Discovery and mechanism of natural products as modulators of histone acetylation.

Authors:  Lilibeth A Salvador; Hendrik Luesch
Journal:  Curr Drug Targets       Date:  2012-07       Impact factor: 3.465

7.  Histone Deacetylase Inhibition Sensitizes PD1 Blockade-Resistant B-cell Lymphomas.

Authors:  Xiaoguang Wang; Brittany C Waschke; Rachel A Woolaver; Zhangguo Chen; Gan Zhang; Anthony D Piscopio; Xuedong Liu; Jing H Wang
Journal:  Cancer Immunol Res       Date:  2019-06-24       Impact factor: 11.151

8.  Design, synthesis, biological evaluation, and structural characterization of potent histone deacetylase inhibitors based on cyclic alpha/beta-tetrapeptide architectures.

Authors:  Ana Montero; John M Beierle; Christian A Olsen; M Reza Ghadiri
Journal:  J Am Chem Soc       Date:  2009-03-04       Impact factor: 15.419

9.  Synthesis and histone deacetylase inhibitory activity of largazole analogs: alteration of the zinc-binding domain and macrocyclic scaffold.

Authors:  Albert A Bowers; Nathan West; Tenaya L Newkirk; Annie E Troutman-Youngman; Stuart L Schreiber; Olaf Wiest; James E Bradner; Robert M Williams
Journal:  Org Lett       Date:  2009-03-19       Impact factor: 6.005

10.  Enantioselective total synthesis of (+)-largazole, a potent inhibitor of histone deacetylase.

Authors:  Arun K Ghosh; Sarang Kulkarni
Journal:  Org Lett       Date:  2008-07-29       Impact factor: 6.005

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.